Lonza Group AG (LONN.SW) is in Healthcare, Diagnostics & Research, based in Switzerland, listed on Swiss. Market cap 39.92B CHF. 52-week range 454.60 to 597.80 CHF. Trailing P/E 37.9. Data as of 2026-10-09.
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and ...